Based on all these observations, we hypothesized that DMF could block inflammatory pathways intrinsic to CLL cells or that are activated after TLR9 triggering and could target the vulnerability of CLL cells linked to both IkBz and NRF2 overexpression. This evidence concerns the gene TLR9 and B-cell chronic lymphocytic leukemia.